May 17, 2019 – ANAUK, Inc. (NYSE: AA), the leading provider of real-world applications for AI Eye Screening ™ systems, announced today that it has expanded its presence in Germany.
Since the Mergentheim Diabetes Center adopted the EyeArt AI Eye Screening System in October 2018, thousands of people with diabetes have been screened for diabetic retinopathy (RD). Approximately 10% of confirmed cases. This center is the first diabetes clinic in Germany to use artificial intelligence to track diabetic retinopathy, which is the leading cause of loss of vision in adults at work.
The iAart iScreening System enables real-time clinical DR screening for any physician, allowing diabetic patients to quickly and accurately identify patients who may be associated with DR during regular medical visits. Capture an image from the patient's background and transfer it to the visual art system to get a DR reading result that is read in 60 seconds and made from a PDF report. The iAart system allows eye care professionals to focus on vision preservation treatment without tracking RD.
More than 20,000 people with diabetes mellitus at the Mergentheim Diabetes Center receive diabetes care every year. Prior to the introduction of the iAart system, patients had to be treated separately by out-of-hospital ophthalmologists. This process unnecessarily burdened patients and patients often did not receive the necessary assessments.
Professor Thomas Haak, MD, Member of the Diabetes Foundation and Board Member and Executive Director of the Merengent Haim Diabetes Center, said: "The Eye Eye Artificial Intelligence Screening System helps to improve the treatment of diabetics." Now that we have a check-up at "With the accuracy and convenience of the iAart system, we can quickly and efficiently check and treat DR," he added. non RD patients may feel comfortable with their exams each year, "Patients may be relieved to see retinopathy progressing silently and treated before they lose vision."
In Germany, about 7.5 million people have diabetes mellitusMore than 2,500 patients die from diabetic retinopathy every year. According to the German guidelines, patients at risk are recommended for annual examinations, but this can also be difficult due to the lack of ophthalmologists. The Merengent Haim Diabetes Center addresses the serious complications associated with diabetes by introducing the ocular art system within the clinic and is tracking 10 to 15 patients with vision threatening disease every day.
Kaushal Solanki, founder and CEO of Ainuc, said: "Last year we started collaborating with the Mergentheim diabetes center with great potential and the possibility of introducing the iAart system into Badmergentheim." Now we are spreading our success stories to clinics in all over Germany and testing all the looks in the world. "" We are delighted to see that this has turned into real and meaningful results for diabetics in the Mergentheim community. I am striving to realize my sense of mission. "
Overview of Diabetic Retinopathy (DR)
Diabetic retinopathy (DR) is one of the diabetic complications caused by damage to the vessels of the tissues that detect light in the retina. It is a silent disease that initially causes no symptoms or only a slight decline in vision, but ultimately can lead to blindness. This disease can occur in anyone with type 1 or type 2 diabetes. RD is estimated to occur in one-third of all diabeticsAnd it is the leading cause of vision loss at full working age.
Although all diabetic patients are recommended to undergo RD testing, less than half of the patients are actually tested annually, even in developed countries. In Germany, more than 1130 diabetics per ophthalmologist There is absolutely no shortage of ophthalmologists that meet the RD test needed for diabetic patients. Even patients who receive an annual eye exam will have to wait several weeks or several months for an ophthalmological examination for a RD test.
Overview of EyeArt AI Eye Screening System
The Eye Eye Intelligence Artificial Screening System is the most tested DR automatic detection artificial intelligence technology with more than 2 million images collected in today's clinical environment and more than 500,000 patients in hospitals worldwide. The iAart system was developed with funding from the US National Institutes of Health (NIH), accredited by the United Kingdom National Health Service (NHS), the European Union CE Mark and Health Canada. Canada). In the United States, federal law restricts use for research purposes only.
Video: Diabetes Center Mergentheim Diabetes Eye Artificial Intelligence Eye Screening System for Diabetic Retinopathy (VIDEO: Learn more about the EyeArt AI Eye Screening System for Diabetic Retinopathy at the Mergentheim Diabetes Center) bit.ly/2VL5PXO)
Overview of Eyenuk, Inc.
Eyenuk, Inc., a global provider of AI technology and services, is the world's leading provider of AI Eye Screening ™ for automated disease surveillance in the real world and biomarkers without AI for risk assessment and disease monitoring. IA Predictive Biomarkers ™. The mission of Aninuq is to inspect every eye of the world for the timely diagnosis of life-threatening diseases such as diabetic retinopathy, glaucoma, age-related macular degeneration, risk of stroke, cardiovascular disease and Alzheimer's disease.
EyeArt is a registered trademark of Eyenuk, Inc. Prokofyeva E, Zrenner E. Epidemiology of major eye diseases leading to blindness in Europe: a review of the literature. Ophthalmic Research. 2012; 47: 171-188. doi: 10.1159 / 000329603
 International Diabetes Federation (2017) IDF Diabetes Atlas, 8th ed. http://www.idf.org/diabetesatlas
 Yau JW, Rogers SL, Kawasaki R, and others. Overall prevalence and major risk factors for diabetic retinopathy. Diabetes Care. 2012; 35: 556-64. doi: 10.2337 / dc11-1909
 Prokofyeva E, Zrenner E. Epidemiology of major eye diseases leading to blindness in Europe: a review of the literature. Ophthalmic Research. 2012; 47: 171-188. doi: 10.1159 / 000329603
Business Wire (businesswire.com) View the original page: https://www.businesswire.com/news/home/20190516005207/en/[이 보도자료는 해당 기업에서 원하는 언어로 작성한 원문을 한국어로 번역한 것이다. 그러므로 번역문의 정확한 사실 확인을 위해서는 원문 대조 절차를 거쳐야 한다. 처음 작성된 원문만이 공식적인 효력을 갖는 발표로 인정되며 모든 법적 책임은 원문에 한해 유효하다.]
Share press releases